Literature DB >> 7711141

Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells.

H Lochmüller1, A Jani, J Huard, S Prescott, M Simoneau, B Massie, G Karpati, G Acsadi.   

Abstract

Early region 1 (E1)-deleted human adenovirus (AV) recombinants have been shown to be powerful tools of gene transfer in vivo and in vitro and are considered for application in human gene therapy. We could detect increasing titers of E1-containing adenovirus in two independent E1 + E3-deleted recombinant AV stocks during multiple passages in 293 cells, most likely due to a recombinant event with the host cell genome. We show the deleterious effects of this E1-containing, mostly replication-competent AV subpopulation in vivo and compare different screening methods of AV stocks for its detection. These considerations are important for the safety of human gene therapy trials.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711141     DOI: 10.1089/hum.1994.5.12-1485

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  42 in total

1.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches.

Authors:  Pete Murakami; Menzo Havenga; Farah Fawaz; Ronald Vogels; Giuseppe Marzio; Erno Pungor; Jim Files; Linh Do; Jaap Goudsmit; Michael McCaman
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer.

Authors:  E J Kremer; S Boutin; M Chillon; O Danos
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

5.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

6.  Recombinational construction in Escherichia coli of infectious adenoviral genomes.

Authors:  J Crouzet; L Naudin; C Orsini; E Vigne; L Ferrero; A Le Roux; P Benoit; M Latta; C Torrent; D Branellec; P Denèfle; J F Mayaux; M Perricaudet; P Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

7.  Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette.

Authors:  B Massie; F Couture; L Lamoureux; D D Mosser; C Guilbault; P Jolicoeur; F Bélanger; Y Langelier
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.

Authors:  M I Gorziglia; M J Kadan; S Yei; J Lim; G M Lee; R Luthra; B C Trapnell
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.

Authors:  Zachary C Hartman; Daniel M Appledorn; Delila Serra; Oliver Glass; Todd B Mendelson; Timothy M Clay; Andrea Amalfitano
Journal:  Virology       Date:  2008-02-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.